The Serum Institute of India (SII) has announced that it will soon commence Phase I and Phase II trials for its indigenous dengue vaccine, Dengusiil, in India. This development comes after the successful Phase-I trial conducted in Australia. Dengusiil aims to provide a much-needed solution to dengue fever, a mosquito-borne viral infection that affects a significant number of people in India each year. The trials will evaluate the safety and efficacy of the vaccine on a larger population in India. With the initiation of these trials, India is taking a major step forward in developing its own indigenous dengue vaccine, potentially reducing the burden of this disease in the country.
Serum Institute of India to Begin Trials for Indigenous Dengue Vaccine
The Serum Institute of India (SII) is set to begin Phase I and Phase II trials of its Dengusiil vaccine in India, following a successful Phase-I trial in Australia. This move brings India closer to developing its first indigenous dengue vaccine.
Latest from Blog
Manu Chopra, CEO of Karya Inc., emphasized the importance of utilizing artificial intelligence (AI) to reduce
Italy has decided to withdraw from China's Belt and Road Initiative, becoming the only G7 nation
Zerodha's top executives collectively received a remuneration of about ₹200 crore in the financial year 2022-23,
New research suggests that radiotherapy may not be necessary for many patients with ductal carcinoma in
The US Space Force's X-37B space plane is gearing up for its seventh mission, after landing
